{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:23:22Z","timestamp":1793744602145,"version":"4.6.1"},"reference-count":134,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007547","name":"Fourth Military Medical University","doi-asserted-by":"publisher","award":["2023RCJB10"],"award-info":[{"award-number":["2023RCJB10"]}],"id":[{"id":"10.13039\/501100007547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070681"],"award-info":[{"award-number":["82070681"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iLIVER"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.iliver.2025.100195","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:36:30Z","timestamp":1757781390000},"page":"100195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pathogenesis of metabolic dysfunction-associated steatotic liver disease and donor liver damage"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9034-007X","authenticated-orcid":false,"given":"Chuheng","family":"Gou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.iliver.2025.100195_bib2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.iliver.2025.100195_bib3","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2025.100195_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/j.gastro.2023.11.007","article-title":"Nonalcoholic fatty liver disease gets renamed as metabolic dysfunction-associated steatotic liver disease: progress but with challenges","volume":"166","author":"Allen","year":"2024","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.iliver.2025.100195_bib5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jhep.2023.10.011","article-title":"MASLD emerging from the fog of fatty liver","volume":"80","author":"Marchesini","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.iliver.2025.100195_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.iliver.2025.100195_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106175","article-title":"The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease","volume":"98","author":"Hardy","year":"2020","journal-title":"Contemp Clin Trials"},{"issue":"2","key":"10.1016\/j.iliver.2025.100195_bib8","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.iliver.2025.100195_bib9","first-page":"23","author":"Huang","year":"2024"},{"key":"10.1016\/j.iliver.2025.100195_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jare.2024.02.007","article-title":"A narrative review about cognitive impairment in Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD): another matter to face through a holistic approach","volume":"68","author":"Meroni","year":"2025","journal-title":"J Adv Res"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/1744666X.2023.2294046","article-title":"The pathophysiology of MASLD: an immunometabolic perspective","volume":"20","author":"Schw\u00e4rzler","year":"2024","journal-title":"Expet Rev Clin Immunol"},{"issue":"22","key":"10.1016\/j.iliver.2025.100195_bib12","first-page":"3484","article-title":"Research progress in the pathogenesis of non-alcoholic fatty liver disease and potential drugs","volume":"45","author":"Ye","year":"2023","journal-title":"Heb Med J"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib13","first-page":"571","article-title":"Research progress on influencing factors of non-alcoholic fatty liver disease","volume":"22","author":"Liu","year":"2022","journal-title":"Moder Health Preserv"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.iliver.2025.100195_bib15","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.iliver.2025.100195_bib16","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.iliver.2025.100195_bib17","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/hep.29522","article-title":"Nuclear Lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease","volume":"67","author":"Brady","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.iliver.2025.100195_bib18","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1038\/s41467-023-42420-1","article-title":"RING finger protein 13 protects against nonalcoholic steatohepatitis by targeting STING-relayed signaling pathways","volume":"14","author":"Lin","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/nu15030687","article-title":"Understanding NAFLD: from case identification to interventions, outcomes, and future perspectives","volume":"15","author":"Clayton-Chubb","year":"2023","journal-title":"Nutrients"},{"issue":"682","key":"10.1016\/j.iliver.2025.100195_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adc9653","article-title":"Hepatocytes demarcated by EphB2 contribute to the progression of nonalcoholic steatohepatitis","volume":"15","author":"Xiao","year":"2023","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib21","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/liv.15845","article-title":"Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus","volume":"44","author":"Lavrado","year":"2024","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib22","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jhep.2023.05.007","article-title":"Therapeutic opportunities for the treatment of NASH with genetically validated targets","volume":"79","author":"Lind\u00e9n","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2025.100195_bib23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib24","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/hep.31771","article-title":"Liver-specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis, and hepatocellular cancer","volume":"74","author":"Newberry","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib25","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jcmgh.2021.11.007","article-title":"TM6SF2\/PNPLA3\/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models","volume":"13","author":"Longo","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.iliver.2025.100195_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102866","article-title":"MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD","volume":"57","author":"Meroni","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148559","article-title":"Addressing dyslipidemic risk beyond LDL-cholesterol","volume":"132","author":"Tall","year":"2022","journal-title":"J Clin Investig"},{"issue":"11","key":"10.1016\/j.iliver.2025.100195_bib28","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.3390\/ijms26115164","article-title":"Polygenic risk score for metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a narrative review","volume":"26","author":"Kanda","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.iliver.2025.100195_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102389","article-title":"Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population","volume":"48","author":"Rashu","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/apa.17475","article-title":"Irisin as a marker of hepatic steatosis in children with metabolic dysfunction-associated steatotic liver disease","volume":"114","author":"Zdanowicz","year":"2025","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.iliver.2025.100195_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113290","article-title":"Diet-gut microbiota-epigenetics in metabolic diseases: from mechanisms to therapeutics","volume":"153","author":"Li","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"20","key":"10.1016\/j.iliver.2025.100195_bib32","article-title":"Epigenetic regulation of hepatic lipid metabolism by DNA methylation","volume":"10","author":"Wang","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41392-023-01333-7","article-title":"Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"6","key":"10.1016\/j.iliver.2025.100195_bib34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/dna.2023.0410","article-title":"m6A RNA methylation and implications for hepatic lipid metabolism","volume":"43","author":"Ming","year":"2024","journal-title":"DNA Cell Biol"},{"issue":"5","key":"10.1016\/j.iliver.2025.100195_bib35","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbalip.2018.02.003","article-title":"FTO promotes SREBP1c maturation and enhances CIDEC transcription during lipid accumulation in HepG2 cells","volume":"1863","author":"Chen","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib36","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000618","article-title":"Recent advances in MASLD genetics: insights into disease mechanisms and the next frontiers in clinical application","volume":"9","author":"Chen","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.iliver.2025.100195_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol Metabol"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab"},{"issue":"8","key":"10.1016\/j.iliver.2025.100195_bib39","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.2337\/dc18-0071","article-title":"Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars","volume":"41","author":"Luukkonen","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.iliver.2025.100195_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101823","article-title":"Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model","volume":"78","author":"Iannone","year":"2023","journal-title":"Mol Metabol"},{"issue":"5","key":"10.1016\/j.iliver.2025.100195_bib41","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jhep.2023.01.014","article-title":"Inhibition of VEGF-B signaling prevents non-alcoholic fatty liver disease development by targeting lipolysis in the white adipose tissue","volume":"78","author":"Falkevall","year":"2023","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.iliver.2025.100195_bib42","first-page":"S10","article-title":"Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity","volume":"59","author":"Bansal","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.iliver.2025.100195_bib43","doi-asserted-by":"crossref","first-page":"s68","DOI":"10.5604\/01.3001.0010.5499","article-title":"Cross-talk between bile acids and gastro-intestinal and thermogenic hormones: clues from bariatric surgery","volume":"16","author":"Garruti","year":"2017","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.iliver.2025.100195_bib44","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis","volume":"82","author":"Souza","year":"2025","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib46","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib47","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058046","article-title":"Protein kinase C\u03b5 modulates insulin receptor localization and trafficking in mouse embryonic fibroblasts","volume":"8","author":"Pedersen","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.iliver.2025.100195_bib49","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/ijms18071447","article-title":"The role of growth hormone and insulin-like growth factor-I in the liver","volume":"18","author":"Takahashi","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.iliver.2025.100195_bib50","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.dld.2018.08.012","article-title":"Association of non-alcoholic fatty liver disease with thyroid function: a systematic review and meta-analysis","volume":"50","author":"Guo","year":"2018","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.iliver.2025.100195_bib51","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.iliver.2025.100195_bib52","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jhep.2018.01.035","article-title":"Prolactin improves hepatic steatosis via CD36 pathway","volume":"68","author":"Zhang","year":"2018","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.iliver.2025.100195_bib53","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3390\/biology11081237","article-title":"Adipokines in non-alcoholic fatty liver disease: are we on the road toward new biomarkers and therapeutic targets?","volume":"11","author":"Francisco","year":"2022","journal-title":"Biology"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib54","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2304157","article-title":"Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus","volume":"16","author":"Forlano","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.iliver.2025.100195_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1297378","article-title":"A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease","volume":"14","author":"Mart\u00ednez-Sanz","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.iliver.2025.100195_bib57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejim.2023.10.002","article-title":"Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations?","volume":"119","author":"Portincasa","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.iliver.2025.100195_bib58","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.5604\/01.3001.0010.5493","article-title":"Bile acid physiology","volume":"16","author":"Di Ciaula","year":"2017","journal-title":"Ann Hepatol"},{"issue":"41","key":"10.1016\/j.iliver.2025.100195_bib59","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.3748\/wjg.v22.i41.9096","article-title":"Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis","volume":"22","author":"Chackelevicius","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib60","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1053\/j.gastro.2019.06.028","article-title":"Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease","volume":"157","author":"Schwimmer","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2307568","article-title":"Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation","volume":"16","author":"Min","year":"2024","journal-title":"Gut Microbes"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib62","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ecl.2023.01.003","article-title":"Lipid disorders and metabolic-associated fatty liver disease","volume":"52","author":"Anwar","year":"2023","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"12","key":"10.1016\/j.iliver.2025.100195_bib63","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.ajpath.2023.08.007","article-title":"The role of endoplasmic reticulum in lipotoxicity during metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis","volume":"193","author":"Venkatesan","year":"2023","journal-title":"Am J Pathol"},{"key":"10.1016\/j.iliver.2025.100195_bib64","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.3389\/fimmu.2018.03083","article-title":"The C\/EBP homologous protein (CHOP) transcription factor functions in endoplasmic reticulum stress-induced apoptosis and microbial infection","volume":"9","author":"Hu","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib65","doi-asserted-by":"crossref","first-page":"G77","DOI":"10.1152\/ajpgi.00301.2011","article-title":"Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis","volume":"302","author":"Kakisaka","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.iliver.2025.100195_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174457","article-title":"Downregulation of activating transcription factor 4 attenuates lysophosphatidycholine-induced inflammation via the NF-\u03baB pathway","volume":"911","author":"Gong","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib67","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jhep.2018.06.008","article-title":"Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease","volume":"69","author":"Lebeaupin","year":"2018","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib68","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.18632\/aging.203817","article-title":"Hesperidin suppresses ERS-induced inflammation in the pathogenesis of non-alcoholic fatty liver disease","volume":"14","author":"Xie","year":"2022","journal-title":"Aging"},{"issue":"7","key":"10.1016\/j.iliver.2025.100195_bib69","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/emboj.2011.52","article-title":"The unfolded protein response transducer IRE1\u03b1 prevents ER stress-induced hepatic steatosis","volume":"30","author":"Zhang","year":"2011","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib70","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41392-023-01570-w","article-title":"Endoplasmic reticulum stress: molecular mechanism and therapeutic targets","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.iliver.2025.100195_bib71","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202149641","article-title":"The \u201cDomino effect\u201d in MASLD: the inflammatory cascade of steatohepatitis","volume":"54","author":"Mladeni\u0107","year":"2024","journal-title":"Eur J Immunol"},{"issue":"87","key":"10.1016\/j.iliver.2025.100195_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add1599","article-title":"NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis","volume":"8","author":"Marinovi\u0107","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.iliver.2025.100195_bib74","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fimmu.2018.00441","article-title":"NKG2D: a master regulator of immune cell responsiveness","volume":"9","author":"Wensveen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.iliver.2025.100195_bib75","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3389\/fimmu.2018.01994","article-title":"Mucosal-associated invariant T cells improve nonalcoholic fatty liver disease through regulating macrophage polarization","volume":"9","author":"Li","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.iliver.2025.100195_bib76","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/s41591-021-01344-3","article-title":"XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis","volume":"27","author":"Deczkowska","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.iliver.2025.100195_bib77","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jcmgh.2023.03.002","article-title":"The multifaceted roles of macrophages in NAFLD pathogenesis","volume":"15","author":"Vonderlin","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.iliver.2025.100195_bib78","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.7150\/ijbs.47143","article-title":"Kupffer cells in non-alcoholic fatty liver disease: friend or foe?","volume":"16","author":"Chen","year":"2020","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.iliver.2025.100195_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2022.109217","article-title":"Chronic high-fat diet induces galectin-3 and TLR4 to activate NLRP3 inflammasome in NASH","volume":"112","author":"Li","year":"2023","journal-title":"J Nutr Biochem"},{"issue":"11","key":"10.1016\/j.iliver.2025.100195_bib80","article-title":"Understanding the complex macrophage landscape in MASLD","volume":"6","author":"De Ponti","year":"2024","journal-title":"JHEP Rep"},{"issue":"7","key":"10.1016\/j.iliver.2025.100195_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166810","article-title":"FABP4 in LSECs promotes CXCL10-mediated macrophage recruitment and M1 polarization during NAFLD progression","volume":"1869","author":"Zhou","year":"2023","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib82","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2221485","article-title":"Akkermansia muciniphila inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated \u03b3\u03b4T17 cell and macrophage polarization","volume":"15","author":"Han","year":"2023","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib83","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jhep.2019.03.014","article-title":"Macrophage p38\u03b1 promotes nutritional steatohepatitis through M1 polarization","volume":"71","author":"Zhang","year":"2019","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.iliver.2025.100195_bib84","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41574-022-00675-6","article-title":"Macrophage functional diversity in NAFLD\u2014more than inflammation","volume":"18","author":"Barreby","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.iliver.2025.100195_bib85","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jhep.2021.07.032","article-title":"Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis","volume":"75","author":"Wang","year":"2021","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.iliver.2025.100195_bib86","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/cells14100740","article-title":"Activated immune and complement C3 are potential contributors in MASH via stimulating neutrophil extracellular traps","volume":"14","author":"Liu","year":"2025","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib87","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5483\/BMBRep.2024-0058","article-title":"Neutrophils in MASLD and MASH","volume":"58","author":"Shrestha","year":"2025","journal-title":"BMB Rep"},{"issue":"16","key":"10.1016\/j.iliver.2025.100195_bib88","doi-asserted-by":"crossref","first-page":"9380","DOI":"10.3390\/ijms23169380","article-title":"microRNA-223 suppresses human hepatic stellate cell activation partly via regulating the actin cytoskeleton and alleviates fibrosis in organoid models of liver injury","volume":"23","author":"Ariyachet","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib89","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/hep.31889","article-title":"The emerging role of B cells in the pathogenesis of NAFLD","volume":"74","author":"Barrow","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.iliver.2025.100195_bib90","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/hep.31755","article-title":"Microbiota-driven activation of intrahepatic B cells aggravates NASH through innate and adaptive signaling","volume":"74","author":"Barrow","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib91","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.32481","article-title":"The B side of B cells in NAFLD","volume":"76","author":"Barrow","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.iliver.2025.100195_bib92","article-title":"The multifaceted roles of B lymphocytes in metabolic dysfunction-associated steatotic liver disease","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.iliver.2025.100195_bib93","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2023.04.037","article-title":"Intestinal B cells license metabolic T-cell activation in NASH microbiota\/antigen-independently and contribute to fibrosis by IgA-FcR signalling","volume":"79","author":"Kotsiliti","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.iliver.2025.100195_bib94","article-title":"CD4+ T cell activation and inflammation in NASH-related fibrosis","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.iliver.2025.100195_bib95","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cmet.2021.04.018","article-title":"PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease","volume":"33","author":"Moreno-Fernandez","year":"2021","journal-title":"Cell Metab"},{"issue":"7593","key":"10.1016\/j.iliver.2025.100195_bib96","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"issue":"7854","key":"10.1016\/j.iliver.2025.100195_bib97","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.iliver.2025.100195_bib98","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","article-title":"Metabolic reprogramming in liver fibrosis","volume":"36","author":"Horn","year":"2024","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib99","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jhep.2024.07.034","article-title":"Targeting the liver clock improves fibrosis by restoring TGF-\u03b2 signaling","volume":"82","author":"Crouchet","year":"2025","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.iliver.2025.100195_bib100","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14433","article-title":"Intent-to-treat survival in liver transplantation has not improved in 3 decades due to donor shortage relative to waitlist growth","volume":"35","author":"Dunson","year":"2021","journal-title":"Clin Transpl"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib101","first-page":"582","article-title":"Application of reduced volume liver transplantation in rat fatty liver supplying liver transplantation model","volume":"22","author":"Zhao","year":"2018","journal-title":"J Clin Rehabilitative Tissue Eng Res"},{"key":"10.1016\/j.iliver.2025.100195_bib102","first-page":"1","article-title":"Opportunities and challenges of marginal donorliver","author":"Lu","year":"2024","journal-title":"Organ Transpl"},{"issue":"2","key":"10.1016\/j.iliver.2025.100195_bib103","first-page":"162","article-title":"Application and progress of fatty degenerative liver supply in liver transplantation","volume":"10","author":"Yuan","year":"2022","journal-title":"Prac J Organ Transpl"},{"issue":"5","key":"10.1016\/j.iliver.2025.100195_bib104","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/TP.0b013e3181e86b11","article-title":"Prediction of graft dysfunction based on extended criteria donors in the model for end-stage liver disease score era","volume":"90","author":"Brice\u00f1o","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.iliver.2025.100195_bib105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijsu.2020.05.024","article-title":"Expanding the donor pool for liver transplantation with marginal donors","volume":"82S","author":"Goldaracena","year":"2020","journal-title":"Int J Surg"},{"issue":"9","key":"10.1016\/j.iliver.2025.100195_bib106","first-page":"568","article-title":"Challenges in liver transplant 2023","volume":"162","author":"Rabinowich","year":"2023","journal-title":"Harefuah"},{"issue":"10","key":"10.1016\/j.iliver.2025.100195_bib107","first-page":"922","article-title":"Effects of fatty degenerative liver supply on the prognosis of live liver transplantation in children","volume":"60","author":"Yang","year":"2022","journal-title":"Chin J Surg"},{"issue":"6","key":"10.1016\/j.iliver.2025.100195_bib108","first-page":"421","article-title":"Retrospective study on clinical application of fatty degenerative liver","volume":"30","author":"Ke","year":"2022","journal-title":"J Hepatobil Surg"},{"issue":"7","key":"10.1016\/j.iliver.2025.100195_bib109","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/tri.13828","article-title":"Application of ischaemia-free liver transplantation improves prognosis of patients with steatotic donor livers - a retrospective study","volume":"34","author":"Chen","year":"2021","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.iliver.2025.100195_bib110","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/TP.0000000000004291","article-title":"Impact of donor liver macrovesicular steatosis on deceased donor yield and posttransplant outcome","volume":"107","author":"Kwong","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.iliver.2025.100195_bib111","article-title":"Donor small-droplet macrovesicular steatosis affects liver transplant outcome in HCV-negative recipients","volume":"2019","author":"Ferri","year":"2019","journal-title":"Chin J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.iliver.2025.100195_bib112","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4166\/kjg.2025.013","article-title":"Application of steatotic donor livers in liver transplantation","volume":"85","author":"Li","year":"2025","journal-title":"Korean J Gastroenterol"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib113","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.transproceed.2019.11.024","article-title":"Rapid decrease in liver graft steatosis in the early post-transplant period: a blinded and randomized study","volume":"52","author":"Mangus","year":"2020","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.iliver.2025.100195_bib114","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/ctr.12211","article-title":"Safe use of highly steatotic livers by utilizing a donor\/recipient clinical algorithm","volume":"27","author":"Chavin","year":"2013","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib115","first-page":"449","article-title":"Advances in the study of liver cold ischemia injury with fatty degeneration","volume":"14","author":"Yang","year":"2023","journal-title":"Organ Transpl"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib116","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3390\/ijms22041864","article-title":"Hemorheological and microcirculatory factors in liver ischemia-reperfusion injury-an update on pathophysiology, molecular mechanisms and protective strategies","volume":"22","author":"Nemeth","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib117","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/jcm9030846","article-title":"Ischemia-reperfusion injury in marginal liver grafts and the role of hypothermic machine perfusion: molecular mechanisms and clinical implications","volume":"9","author":"Czigany","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.iliver.2025.100195_bib118","article-title":"Acid ceramidase protects against hepatic ischemia\/reperfusion injury by modulating sphingolipid metabolism and reducing inflammation and oxidative stress","volume":"9","author":"Jiang","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib119","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cbin.12114","article-title":"Lipid droplets, autophagy, and ER stress as key (survival) pathways during ischemia-reperfusion of transplanted grafts","volume":"48","author":"Kami\u0144ska","year":"2024","journal-title":"Cell Biol Int"},{"issue":"1","key":"10.1016\/j.iliver.2025.100195_bib120","first-page":"126","article-title":"Study on the role of oxidative stress response in ischemia-reperfusion injury of marginal donor liver transplantation","volume":"13","author":"Gao","year":"2022","journal-title":"Organ Transpl"},{"issue":"5","key":"10.1016\/j.iliver.2025.100195_bib121","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/JLB.3MA0520-716R","article-title":"IL-17a exacerbates hepatic ischemia-reperfusion injury in fatty liver by promoting neutrophil infiltration and mitochondria-driven apoptosis","volume":"108","author":"Yang","year":"2020","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.iliver.2025.100195_bib122","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.freeradbiomed.2018.06.043","article-title":"IRE1\u03b1 aggravates ischemia reperfusion injury of fatty liver by regulating phenotypic transformation of kupffer cells","volume":"124","author":"Yang","year":"2018","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"10.1016\/j.iliver.2025.100195_bib123","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.3390\/ijms24043067","article-title":"The role of the NLRP3 inflammasome and programmed cell death in acute liver injury","volume":"24","author":"Yu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.iliver.2025.100195_bib124","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/ajt.15399","article-title":"Fatal diffuse pulmonary fat microemboli following reperfusion in liver transplantation with the use of marginal steatotic allografts","volume":"19","author":"Rosenfeld","year":"2019","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.iliver.2025.100195_bib125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257783","article-title":"Mitochondrial respiratory chain and Krebs cycle enzyme function in human donor livers subjected to end-ischaemic hypothermic machine perfusion","volume":"16","author":"Abudhaise","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.iliver.2025.100195_bib126","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3390\/ijms17060807","article-title":"Relevance of endoplasmic reticulum stress cell signaling in liver cold ischemia reperfusion injury","volume":"17","author":"Folch-Puy","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.iliver.2025.100195_bib127","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3390\/ijms19020348","article-title":"Cytoprotective mechanisms in fatty liver preservation against cold ischemia injury: a comparison between IGL-1 and HTK","volume":"19","author":"Panisello-Rosell\u00f3","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.iliver.2025.100195_bib128","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.3390\/ijms19092479","article-title":"Aldehyde dehydrogenase 2 (ALDH2) in rat fatty liver cold ischemia injury","volume":"19","author":"Panisello-Rosell\u00f3","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.iliver.2025.100195_bib129","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbrc.2022.12.055","article-title":"Preliminary mechanism of inhibitor of SGLT2 in fatty liver cold ischemia injury","volume":"646","author":"Yang","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.iliver.2025.100195_bib130","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"Rong","year":"2022","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.iliver.2025.100195_bib131","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000516608","article-title":"Ischemic preconditioning for liver transplantation: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Jakubauskiene","year":"2021","journal-title":"Visc Med"},{"issue":"5","key":"10.1016\/j.iliver.2025.100195_bib132","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035374","article-title":"Prospective, single-centre, randomised controlled trial to evaluate the efficacy and safety of ischaemia-free liver transplantation (IFLT) in the treatment of end-stage liver disease","volume":"10","author":"Huang","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.iliver.2025.100195_bib133","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/ph18030342","article-title":"Side effects of immunosuppressant drugs after liver transplant","volume":"18","author":"Gabrielli","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.iliver.2025.100195_bib134","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001368","article-title":"AASLD Practice Statement on the evaluation and management of metabolic dysfunction-associated steatotic liver disease in children","author":"Xanthakos","year":"2025","journal-title":"Hepatology"}],"container-title":["iLIVER"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947825000532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772947825000532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T22:16:02Z","timestamp":1772921762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772947825000532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":134,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2772947825000532"],"URL":"https:\/\/doi.org\/10.1016\/j.iliver.2025.100195","relation":{},"ISSN":["2772-9478"],"issn-type":[{"value":"2772-9478","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis of metabolic dysfunction-associated steatotic liver disease and donor liver damage","name":"articletitle","label":"Article Title"},{"value":"iLIVER","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iliver.2025.100195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of Tsinghua University Press.","name":"copyright","label":"Copyright"}],"article-number":"100195"}}